Heart failure therapy by GLP-1RAs Although a meta-analysis of large-scale clinical trials suggested that GLP-1RAs reduce heart failure hospitalizations (HHF) by approximately 10% in patients with diabetes at high cardiovascular risk [22, 23], the treatment effects on the risk of HHF in individual trials other than AMPLITUDE-O were not significant (Tables 1, 2)
Fermentable carbohydrate stimulates FFAR2-dependent colonic PYY cell expansion to increase satiety
Weight loss typically continues beyond 48 weeks with these medications, though the rate slows considerably after the first several months
Methods Peptide therapy Synthetic KBP-089 (American Peptide Company, CA, USA) and liraglutide (SynPeptide, Shanghai, China) were dissolved in saline for subcutaneous delivery
Nebenwirkungen von L-Carnitin Da es sich bei L-Carnitin um eine krpereigene Substanz handelt, ist die Vertrglichkeit grundstzlich sehr gut